metastatic colo-rectal cancer, 2005-2008: treatment results

introduction: colo-rectal cancer has 10% prevalence, among all of the cancer proportionally and also it is the third common cancer in the both sexes. two recently introduced active drugs in the treatment of advanced colorectal cancer (acc) are irinotecan and oxaliplatin. the combinations of oxaliplatin (oxa) or irinotecan (iri) with 5fu-lv have been accepted as standard treatment for metastatic colorectal cancer. patients and methods: fifty four patients with colo-rectal cancer who came to the oncology clinic of kermanshah university were assessed over a period of 4 years (2005-2008). all cases in stage iii were treated by folfox, unlike the patients in stage iv treated with folfox during 8 cycles fallowed by folfiri in the same cycles (sequential method). results: the age average was less (49.1 years versus 55 years) than in other studies (6). a parallel analyzation of solid data, overall survival (os), progression free survival (pfs) were 18 and 17.3 months, respectively. conclusion: folfox and folfiri were administrated in 8 cycles each concomitantly (sequential form) which provided considerable response with manageable complications. the result of the treatment in the study was correlated with other trials utilizing more modern procedures of medication like ‘target therapies’ (os; 18.4m for ct versus 19-20m for target therapies).